News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
279,827 Results
Type
Article (14434)
Company Profile (104)
Press Release (265289)
Section
Business (92152)
Career Advice (541)
Deals (16189)
Drug Delivery (65)
Drug Development (38898)
Employer Resources (52)
FDA (6687)
Job Trends (6667)
News (157461)
Policy (14452)
Tag
Academia (476)
Alliances (23754)
Alzheimer's disease (440)
Approvals (6721)
Artificial intelligence (95)
Bankruptcy (152)
Best Places to Work (4851)
Breast cancer (101)
Cancer (713)
Cardiovascular disease (66)
Career advice (465)
Cell therapy (102)
Clinical research (32795)
Collaboration (327)
Compensation (185)
COVID-19 (793)
C-suite (93)
Data (735)
Diabetes (89)
Diagnostics (1563)
Drug pricing (60)
Earnings (35060)
Events (40213)
Executive appointments (331)
FDA (7099)
Funding (208)
Gene therapy (96)
GLP-1 (332)
Government (1325)
Healthcare (4128)
Infectious disease (829)
Inflammatory bowel disease (55)
Interviews (72)
IPO (6393)
Job creations (2139)
Job search strategy (423)
Layoffs (189)
Legal (3481)
Lung cancer (105)
Lymphoma (59)
Manufacturing (130)
Medical device (1904)
Medtech (1906)
Mergers & acquisitions (9988)
Metabolic disorders (245)
Neuroscience (621)
NextGen: Class of 2025 (1790)
Non-profit (666)
Northern California (890)
Obesity (134)
Opinion (120)
Patents (90)
People (29147)
Pharmaceutical (66)
Phase I (8782)
Phase II (13966)
Phase III (12330)
Pipeline (365)
Postmarket research (1430)
Preclinical (3425)
Radiopharmaceuticals (131)
Rare diseases (164)
Real estate (2696)
Regulatory (10416)
Research institute (597)
Resumes & cover letters (72)
Southern California (854)
Startups (1667)
United States (7895)
Vaccines (155)
Weight loss (89)
Date
Today (60)
Last 7 days (324)
Last 30 days (1355)
Last 365 days (15881)
2025 (2190)
2024 (15796)
2023 (15839)
2022 (21100)
2021 (21624)
2020 (20269)
2019 (15926)
2018 (12430)
2017 (14780)
2016 (13709)
2015 (15980)
2014 (12795)
2013 (10820)
2012 (11667)
2011 (12220)
2010 (11142)
Location
Africa (345)
Asia (20993)
Australia (2708)
California (2061)
Canada (911)
China (203)
Colorado (101)
Connecticut (122)
Delaware (76)
Europe (41177)
Florida (328)
Illinois (222)
Indiana (130)
Japan (82)
Kansas (53)
Maryland (262)
Massachusetts (1638)
Minnesota (94)
New Jersey (720)
New York (527)
North Carolina (373)
Northern California (890)
Ohio (59)
Pennsylvania (471)
South America (546)
Southern California (854)
Texas (263)
Virginia (65)
Washington State (153)
279,827 Results for "x4 pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Layoffs
X4 Pharmaceuticals Stumbles Again, Laying Off 30% of Workforce
The headcount reduction will save money that the company will use in developing mavorixafor, its CXCR4 antagonist that last year received FDA approval to treat WHIM syndrome, in the larger patient population with chronic neutropenia.
February 6, 2025
·
1 min read
·
Dan Samorodnitsky
Press Releases
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 3, 2025
February 4, 2025
·
1 min read
Press Releases
X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia
February 6, 2025
·
6 min read
Deals
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 3, 2024
X4 Pharmaceuticals today announced that, effective on May 31, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc.
June 3, 2024
·
1 min read
Press Releases
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome
January 24, 2025
·
10 min read
Press Releases
X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries
February 19, 2025
·
10 min read
Press Releases
X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference
November 14, 2024
·
1 min read
Press Releases
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor - licenced to Norgine for commercialisation in Europe.
January 24, 2025
·
2 min read
Press Releases
X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand
January 14, 2025
·
8 min read
Genetown
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 01, 2024
X4 Pharmaceuticals, a company driven to improve the lives of people with rare diseases of the immune system, announced that, effective on April 30, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.
May 1, 2024
·
1 min read
1 of 27,983
Next
